CalciMedica Inc
calcimedica.comCalciMedica Inc (NASDAQ: CALC) is a clinical-stage biopharmaceutical company developing small-molecule inhibitors of the CRAC (calcium release-activated calcium) channel, targeting the Orai1 protein. The company generates no product revenue, funding operations through equity offerings and debt financing, including a Loan and Security Agreement with Avenue Capital Management II dated February 28, 2025. CalciMedica's lead program targets acute pancreatitis, with the CARPO trial conducted in part in India, and preclinical work points to additional potential indications including chronic pancreatitis and autoimmune diseases such as collagen-induced arthritis. The company is listed on the Nasdaq Capital Market and, as of its 10-K filed March 3, 2026, reported accumulated deficits consistent with a pre-revenue drug development stage. Capital structure leans on at-the-market equity issuances, underwritten public offerings, and venture debt. No product has received marketing approval as of the filing date.
Products & Services
Orally administered CRAC channel inhibitors targeting Orai1. Lead indication: acute pancreatitis (CARPO clinical trial). Preclinical indications include chronic pancreatitis and autoimmune/inflammatory diseases such as collagen-induced arthritis.
Revenue Model
No product revenue as of the 10-K filed March 3, 2026. Operations are funded through equity capital raises, including at-the-market and underwritten public offerings, and venture debt from Avenue Capital Management II.
Customers & Markets
No commercial customers as of the 10-K filed March 3, 2026. End markets, if products are approved, would be hospital and clinical settings treating acute pancreatitis, chronic pancreatitis, and autoimmune diseases.
Geographic Exposure
Primarily United States-based operations. The CARPO clinical trial was conducted in part in India. Regulatory references include FDA (U.S.), EMA (EU), MHRA (UK), and India's DPDP framework, indicating awareness of multi-jurisdiction development pathways.
Financial Snapshot
Loading...
